{"id":69514,"date":"2026-07-07T19:04:42","date_gmt":"2026-07-07T11:04:42","guid":{"rendered":"https:\/\/flcube.com\/?p=69514"},"modified":"2026-07-07T19:05:49","modified_gmt":"2026-07-07T11:05:49","slug":"alphamab-oncology-nanolek-partner-on-armocibart-hemophilia-prophylaxis-for-russian-and-eaeu-markets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69514","title":{"rendered":"Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Alphamab Oncology<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9966:HKG\">HKG: 9966<\/a>) announced a <strong>strategic cooperation agreement<\/strong> with Russian biopharmaceutical company <strong>LLC Nanolek<\/strong>, granting exclusive commercialization rights for <strong>Armocibart (KN057)<\/strong>, a <strong>subcutaneously injected prophylactic treatment<\/strong> for <strong>Hemophilia A and Hemophilia B<\/strong>, across <strong>Russia<\/strong>, the <strong>Eurasian Economic Union (EAEU)<\/strong>, <strong>Azerbaijan<\/strong>, and <strong>Uzbekistan<\/strong>. <\/p>\n\n\n\n<h2 id=\"h-deal-structure-amp-commercial-framework\" class=\"wp-block-heading\">Deal Structure &amp; Commercial Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Alphamab Oncology (HKG: 9966) and LLC Nanolek<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Armocibart (development code: KN057)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Routine prophylaxis of bleeding in Hemophilia A and Hemophilia B patients with or without inhibitors<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Russia, EAEU member states, Azerbaijan, Uzbekistan<\/td><\/tr><tr><td><strong>Rights Granted<\/strong><\/td><td>Exclusive registration, promotion, and commercial operation rights<\/td><\/tr><tr><td><strong>Regulatory Role<\/strong><\/td><td>Nanolek designated as Marketing Authorization Holder (MAH)<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Subcutaneous injection<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-clinical-development-status\" class=\"wp-block-heading\">Product Profile &amp; Clinical Development Status<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Innovation:<\/strong> Prophylactic treatment addressing both <strong>Hemophilia A<\/strong> (factor VIII deficiency) and <strong>Hemophilia B<\/strong> (factor IX deficiency)<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Effective in patients <strong>with or without inhibitors<\/strong> \u2013 critical differentiator given 25-30% of severe hemophilia patients develop inhibitory antibodies<\/li>\n\n\n\n<li><strong>Current Development Stage:<\/strong> <strong>Phase III clinical trials ongoing<\/strong> in hemophilia patients with and without inhibitors<\/li>\n\n\n\n<li><strong>China Timeline:<\/strong> Clinical trials expected to complete by <strong>mid-2027<\/strong><\/li>\n\n\n\n<li><strong>Dosing Advantage:<\/strong> Subcutaneous administration offers significant convenience over intravenous factor replacement therapies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-partnership-rationale\" class=\"wp-block-heading\">Strategic Partnership Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Strategic Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Alphamab Oncology<\/strong><\/td><td>Expands international footprint into strategically important Eurasian markets without establishing local commercial infrastructure; leverages Nanolek&#8217;s established regulatory expertise and market access capabilities<\/td><\/tr><tr><td><strong>Nanolek<\/strong><\/td><td>Diversifies portfolio with innovative hemophilia therapy addressing significant unmet need; strengthens position as preferred partner for international biopharmaceutical companies entering Russian and EAEU markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Nanolek, one of Russia&#8217;s leading biopharmaceutical companies with extensive experience in complex biologics and orphan disease treatments, maintains comprehensive regulatory, manufacturing, and commercial capabilities across the post-Soviet space.<\/p>\n\n\n\n<h2 id=\"h-market-opportunity-amp-regional-context\" class=\"wp-block-heading\">Market Opportunity &amp; Regional Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hemophilia Prevalence:<\/strong> Combined hemophilia population across target territories estimated at 25,000-30,000 patients, with significant undertreatment due to cost and access barriers<\/li>\n\n\n\n<li><strong>Current Treatment Landscape:<\/strong> Dominated by plasma-derived and recombinant factor concentrates requiring intravenous administration multiple times weekly<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Limited access to modern prophylactic therapies, particularly for inhibitor patients who require expensive bypassing agents<\/li>\n\n\n\n<li><strong>Pricing Environment:<\/strong> Orphan drug designation potential supports premium pricing; government healthcare programs increasingly covering advanced hemophilia therapies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-differentiation-amp-clinical-advantages\" class=\"wp-block-heading\">Competitive Differentiation &amp; Clinical Advantages<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Indication:<\/strong> Single product addressing both major hemophilia types represents significant operational advantage over factor-specific therapies<\/li>\n\n\n\n<li><strong>Inhibitor Coverage:<\/strong> Ability to treat inhibitor patients expands addressable market by 25-30% compared to standard factor replacement<\/li>\n\n\n\n<li><strong>Subcutaneous Delivery:<\/strong> Potential for improved patient compliance and quality of life compared to intravenous regimens<\/li>\n\n\n\n<li><strong>Prophylactic Focus:<\/strong> Aligns with global treatment guidelines emphasizing prevention over on-demand treatment<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the Alphamab-Nanolek partnership, clinical development timelines, regulatory approvals, and commercial prospects for Armocibart. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive developments, and geopolitical factors affecting the Eurasian pharmaceutical market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alphamab Oncology (HKG: 9966) announced a strategic cooperation agreement with Russian biopharmaceutical company LLC Nanolek,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":69515,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[187,854,4840,24],"class_list":["post-69514","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-alphamab-oncology","tag-hkg-9966","tag-nanolek","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Alphamab Oncology (HKG: 9966) announced a strategic cooperation agreement with Russian biopharmaceutical company LLC Nanolek, granting exclusive commercialization rights for Armocibart (KN057), a subcutaneously injected prophylactic treatment for Hemophilia A and Hemophilia B, across Russia, the Eurasian Economic Union (EAEU), Azerbaijan, and Uzbekistan.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69514\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets\" \/>\n<meta property=\"og:description\" content=\"Alphamab Oncology (HKG: 9966) announced a strategic cooperation agreement with Russian biopharmaceutical company LLC Nanolek, granting exclusive commercialization rights for Armocibart (KN057), a subcutaneously injected prophylactic treatment for Hemophilia A and Hemophilia B, across Russia, the Eurasian Economic Union (EAEU), Azerbaijan, and Uzbekistan.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69514\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-07T11:04:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-07T11:05:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0702.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"614\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69514#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69514\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets\",\"datePublished\":\"2026-07-07T11:04:42+00:00\",\"dateModified\":\"2026-07-07T11:05:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69514\"},\"wordCount\":472,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69514#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0702.webp\",\"keywords\":[\"Alphamab Oncology\",\"HKG: 9966\",\"Nanolek\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69514#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69514\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69514\",\"name\":\"Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69514#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69514#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0702.webp\",\"datePublished\":\"2026-07-07T11:04:42+00:00\",\"dateModified\":\"2026-07-07T11:05:49+00:00\",\"description\":\"Alphamab Oncology (HKG: 9966) announced a strategic cooperation agreement with Russian biopharmaceutical company LLC Nanolek, granting exclusive commercialization rights for Armocibart (KN057), a subcutaneously injected prophylactic treatment for Hemophilia A and Hemophilia B, across Russia, the Eurasian Economic Union (EAEU), Azerbaijan, and Uzbekistan.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69514#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69514\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69514#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0702.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0702.webp\",\"width\":1080,\"height\":614,\"caption\":\"Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69514#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets - Insight, China&#039;s Pharmaceutical Industry","description":"Alphamab Oncology (HKG: 9966) announced a strategic cooperation agreement with Russian biopharmaceutical company LLC Nanolek, granting exclusive commercialization rights for Armocibart (KN057), a subcutaneously injected prophylactic treatment for Hemophilia A and Hemophilia B, across Russia, the Eurasian Economic Union (EAEU), Azerbaijan, and Uzbekistan.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69514","og_locale":"en_US","og_type":"article","og_title":"Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets","og_description":"Alphamab Oncology (HKG: 9966) announced a strategic cooperation agreement with Russian biopharmaceutical company LLC Nanolek, granting exclusive commercialization rights for Armocibart (KN057), a subcutaneously injected prophylactic treatment for Hemophilia A and Hemophilia B, across Russia, the Eurasian Economic Union (EAEU), Azerbaijan, and Uzbekistan.","og_url":"https:\/\/flcube.com\/?p=69514","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-07T11:04:42+00:00","article_modified_time":"2026-07-07T11:05:49+00:00","og_image":[{"width":1080,"height":614,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0702.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69514#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69514"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets","datePublished":"2026-07-07T11:04:42+00:00","dateModified":"2026-07-07T11:05:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69514"},"wordCount":472,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=69514#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0702.webp","keywords":["Alphamab Oncology","HKG: 9966","Nanolek","Rare \/ orphan disease drugs"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69514#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69514","url":"https:\/\/flcube.com\/?p=69514","name":"Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=69514#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=69514#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0702.webp","datePublished":"2026-07-07T11:04:42+00:00","dateModified":"2026-07-07T11:05:49+00:00","description":"Alphamab Oncology (HKG: 9966) announced a strategic cooperation agreement with Russian biopharmaceutical company LLC Nanolek, granting exclusive commercialization rights for Armocibart (KN057), a subcutaneously injected prophylactic treatment for Hemophilia A and Hemophilia B, across Russia, the Eurasian Economic Union (EAEU), Azerbaijan, and Uzbekistan.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69514#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69514"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=69514#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0702.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0702.webp","width":1080,"height":614,"caption":"Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69514#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0702.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69514"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69514\/revisions"}],"predecessor-version":[{"id":69519,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69514\/revisions\/69519"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/69515"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69514"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69514"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}